Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Jan 7;100(1):259-64.
doi: 10.1073/pnas.0235361100. Epub 2002 Dec 27.

Positive and negative regulation of APP amyloidogenesis by sumoylation

Affiliations

Positive and negative regulation of APP amyloidogenesis by sumoylation

Yonghong Li et al. Proc Natl Acad Sci U S A. .

Erratum in

  • Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):9102

Abstract

Amyloid beta peptide (Abeta) generated from amyloid precursor protein (APP) is central to Alzheimer's disease (AD). Signaling pathways affecting APP amyloidogenesis play critical roles in AD pathogenesis and can be exploited for therapeutic intervention. Here, we show that sumoylation, covalent modification of cellular proteins by small ubiquitin-like modifier (SUMO) proteins, regulates Abeta generation. Increased protein sumoylation resulting from overexpression of SUMO-3 dramatically reduces Abeta production. Conversely, reducing endogenous protein sumoylation with dominant-negative SUMO-3 mutants significantly increases Abeta production. We also show that mutant SUMO-3, K11R, which can only be monomerically conjugated to target proteins, has an opposite effect on Abeta generation to that by SUMO-3, which can form polymeric chains on target proteins. In addition, SUMO-3 immunoreactivity is predominantly detected in neurons in brains from AD, Down's syndrome, and nondemented humans. Therefore, polysumoylation reduces whereas monosumoylation or undersumoylation enhances Abeta generation. These findings provide a regulatory mechanism in APP amyloidogenesis and suggest that components in the sumoylation pathway may be critical in AD onset or progression.

PubMed Disclaimer

Figures

Figure 1
Figure 1
SUMO-3 sumoylation regulates APP processing in 293T cells. (A) Diagram showing APP processing and antibody epitopes used in ELISA: 266.1 and 3D6 for Aβ, 8E5 and AF20 or 192wt for β-NTF, and 8E5 and 2H3 for α-NTF. Drawing not to scale. (B) Dose–effect of SUMO-3 expression on Aβ, β-NTF, and α-NTF generation from cells cotransfected with APP and without or with increasing amounts of SUMO-3 plasmids. All transfections contained 160-ng APP plasmids. The amount of SUMO-3 plasmids used were 0, 40, 160, and 640 ng in transfections corresponding to the columns from left to right. Vector DNAs were supplemented to bring the total amount of DNA to 800 ng for each transfection. A similar dilution scheme was used in other figures as well. The results were expressed as relative to the amount of APP-processing products indicated in each panel to the control. The control was APP transfection alone. (C) Western blot showing dose–effect of SUMO-3 on α-NTF production. Equal amounts of growth media from cells transfected as indicated were probed with 8E5 antibody. (D) Western blot showing SUMO-3 expression and protein sumoylation. Equal amounts of protein from lysates of cells transfected as indicated above were probed with affinity-purified SUMO-3 antibody. Arrows indicate SUMO dimer and trimer. HMW Proteins, high molecular weight proteins. (E) Western blot showing expression and sumoylation/desumoylation of SUMO-3 and mutants. Cells were mock-transfected or transfected with APP and SUMO plasmids, and lysates were probed with anti-SUMO-3 antibody. (F) Effect of SUMO-3 and mutants on Aβ, β-NTF, and α-NTF generation from transfected cells as determined by ELISA. (G) Dose–effect of SUMO-3(11R) on Aβ, β-NTF, and α-NTF generation as determined by ELISA. Each of the above experiments was carried out more than three times with equivalent results as those presented. *, Significantly different from APP transfection alone (P < 0.005, ANOVA post hoc tests).
Figure 2
Figure 2
Effect of SUMO-3 and SUMO-3(G93A) on APP and BACE expression. (A) Pulse–chase study of the kinetics of APP metabolism in 293T cells cotransfected with equal amounts of APP and the plasmid indicated. Immature (I) and mature (M, M2) APP species are indicated. (B) Dose–effect of SUMO-3 and mutant on APP expression. Equal amounts of proteins from lysates of cells transfected with the indicated plasmids for 48 h were probed with an anti-C-terminal APP antibody. (C) Western blot showing dose–effect of SUMO-3 and mutant on BACE expression. Equal amounts of proteins from cells transfected with indicated plasmids for 48 h were probed with an anti-BACE antibody.
Figure 3
Figure 3
Effect of ubiquitination and neddylation on APP processing in 293T cells. (A) Western blot showing expression and conjugation of HisG-tagged ubiquitin and HisG-tagged Nedd-8. Lysates from transfected cells were probed with an anti-HisG antibody. (B) Effect of ubiquitin and Nedd-8 on APP processing as determined by ELISA for Aβ, β-NTF, and α-NTF.
Figure 4
Figure 4
SUMO-3 in human brain and its effect on APP processing in a human neuronal cell line. (A) SUMO-3 immunoreactivity in brain. ND, nondemented. Scale bars represent 20 and 100 μm for high and low magnifications, respectively. (B) Effect of SUMO-3 on Aβ, β-NTF, and α-NTF generation in SK-N-MC cells as determined by ELISA. (C) Schematic diagram summarizing effects of sumoylation on APP amyloidogenesis. Polysumoylation negatively (−) regulates but monosumoylation or undersumoylation positively (+) regulates Aβ production. SUMO proteins are indicated by small white circles.

Similar articles

Cited by

References

    1. Farzan M, Schnitzler C E, Vasilieva N, Leung D, Choe H. Proc Natl Acad Sci USA. 2000;97:9712–9717. - PMC - PubMed
    1. Hussain I, Powell D, Howlett D R, Tew D G, Meek T D, Chapman C, Gloger I S, Murphy K E, Southan C D, Ryan D M, et al. Mol Cell Neurosci. 1999;14:419–427. - PubMed
    1. Sinha S, Anderson J P, Barbour R, Basi G S, Caccavello R, Davis D, Doan M, Dovey H F, Frigon N, Hong J, et al. Nature. 1999;402:537–540. - PubMed
    1. Vassar R, Bennett B D, Babu-Kahn S, Kahn S, Mendiaz E A, Denis P, Teplow D B, Ross S, Amarante P, Loeloff R, et al. Science. 1999;286:735–741. - PubMed
    1. Yan R, Bienkowski M J, Shuck M E, Miao H, Tory M C, Pauley A M, Brashier J R, Stratman N C, Mathews W R, Buhl A E, et al. Nature. 1999;402:533–537. - PubMed

Publication types

MeSH terms

LinkOut - more resources